Axq Capital, LP Cullinan Oncology, Inc. Transaction History
Axq Capital, LP
- $249 Billion
- Q1 2025
A detailed history of Axq Capital, LP transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Axq Capital, LP holds 14,255 shares of CGEM stock, worth $111,759. This represents 0.04% of its overall portfolio holdings.
Number of Shares
14,255Holding current value
$111,759% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding CGEM
# of Institutions
155Shares Held
68.6MCall Options Held
15.6KPut Options Held
17.9K-
Bio Impact Capital LLC Cambridge, MA7.65MShares$60 Million10.72% of portfolio
-
Bvf Inc San Francisco, CA5.75MShares$45.1 Million1.91% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.86MShares$30.3 Million0.74% of portfolio
-
Black Rock Inc. New York, NY3.55MShares$27.8 Million0.0% of portfolio
-
Chi Advisors LLC New York, NY3.41MShares$26.8 Million15.23% of portfolio
About Cullinan Oncology, Inc.
- Ticker CGEM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,612,200
- Market Cap $358M
- Description
- Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...